July 2, 2019
Fumiyoshi Sakai, Director, Equity Research, Credit Suisse Securities (Japan) The future of Bristol-Myers Squibb/Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) hinges on the final data expected to arrive this summer from CheckMate-227, a PIII study gauging the drug plus the anti-CTLA-4...read more